Trial site
Goztepe Prof. Dr. Suleyman Yalcin City Hospital
Istanbul, 34772, TürkiyeNot linked to an institution yet
- 10running trials
- 3closed trials
The trials here
What the 13 trials at this site are about, from their registry records.
- Phase
- Phase 37 trials
- Phase 1/21 trial
- Phase 21 trial
- Status
- Recruiting7 trials
- Active, not recruiting3 trials
- Completed2 trials
- Terminated1 trial
- Lead sponsor
- Daiichi Sankyo4 trials
- BioNTech SE2 trials
- Bilinç Doğruöz Karatekin1 trial
- Genmab1 trial
- Hacettepe University1 trial
- and 4 more
Running trials
Recruiting
Interoception and Symptom Perception in Acute COPD Exacerbation
NCT07719231· Saglik Bilimleri Universitesi· Source
Contact: Gamze Koyutürk, Asst. Prof
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126· Phase 3· Daiichi Sankyo· Source
Recruiting
Effect of Emotion-Focused Acceptance and Commitment Therapy on Obsessive-Compulsive Disorder Symptom Severity
NCT07622654· Mehmet Emrah Karadere· Source
Contact: Mehmet Emrah Karadere
Recruiting
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT07111520· Phase 1/2· BioNTech SE· Source
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478· Phase 3· Daiichi Sankyo· Source
Recruiting
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
NCT06712355· Phase 3· BioNTech SE· Source
Active, not recruiting
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824· Phase 3· Genmab· Source
Recruiting
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
NCT06203210· Phase 3· Daiichi Sankyo· Source
Contact: Principal Investigator
Active, not recruiting
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
NCT05215340· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
NCT04821622· Phase 3· Pfizer· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error